The Society for Healthcare Epidemiology of America (SHEA), Association for Professionals in Infection Control and Epidemiology (APIC), Pediatric Infectious Diseases Society (PIDS) and the Association of periOperative Registered Nurses (AORN) state that they are pleased that the Food and Drug Administration (FDA) has granted 510(k) clearance to a new pediatric face mask developed by Kimberly-Clark Health Care (KCHC). The KCHC pediatric face mask is the only scientifically validated mask designed for children 5-12 years old.
The organizations add: "As pediatric healthcare workers who provide care for children, as well as manage their infection prevention, the groups urged KCHC and other manufacturers to seek formal FDA clearance and validation of their pediatric surgical face mask in preventing droplet particle spread, the chief way influenza and other respiratory pathogens are transmitted. Until now, no pediatric face mask had been reviewed by the FDA for efficacy in preventing droplet spread.
"The professional organizations collaborated with KCHC to define key considerations that shaped the product design and recommended uses. KCHC has been granted a 510(k) clearance by the FDA to market their Childs Face Mask as a Class II medical device.
"Face masks are widely used during respiratory viral season, often in outpatient settings like emergency departments and clinics to prevent the spread of influenza and other respiratory pathogens among symptomatic patients. They are also used on infected patients, during necessary transport around the hospital. The groups hope the FDA clearance of KCHCs Childs Face Mask leads the way for inclusion of pediatric face masks into the Strategic National Stockpile, a pre-determined national supply of medicines and medical supplies which are available to be dispensed to healthcare facilities and communities in the event of a national public health crisis."
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.